A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Inclusion Criteria:

- Have received a diagnosis of SLE at least 24 weeks prior to screening, meeting the
American College of Rheumatology (ACR) 1982 revised criteria OR the 2012 Systemic
Lupus Erythematosus International Collaborating Clinics (SLICC) criteria.

- Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive
anti-double-stranded deoxyribonucleic acid (dsDNA) as assessed by a central laboratory
at screening.

- Have a SLEDAI-2K score ≥4 based on clinical symptoms (not including lab values) at
randomization.

- Have active arthritis and/or active rash as defined by the SLEDAI-2K at randomization.

Exclusion Criteria:

- Have active severe lupus nephritis.

- Have active severe central nervous system (CNS) lupus.

- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute an unacceptable risk when taking investigational product or interfere with
the interpretation of data.

- Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
infection.

- Are currently receiving oral corticosteroids at doses >20-milligrams per day of
prednisone (or equivalent) or have adjusted the dose of corticosteroids within 2 weeks
of planned randomization.

- Have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory
drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and
symptoms of SLE) within 4 weeks of planned randomization.

- Have started treatment with or adjusted the dose of an antimalarial within 12 weeks of
planned randomization.

- Have started treatment with or adjusted the dose of an immunosuppressant within 12
weeks of planned randomization.

- Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to
screening.